New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:05 EDTEXASExact Sciences risk/reward positive, says Canaccord
Canaccord said the scenario analysis of upcoming catalysts suggests positive risk/reward for the shares of Exact Sciences. The firm cited its potential for reimbursement approvals form both the CMS and commercial payers. Shares of Exact Sciences remain Buy rated with a $21 price target.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:04 EDTEXASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTEXASExact Sciences downgraded to Neutral from Buy at Goldman
Goldman downgraded Exact Sciences to Neutral to reflect lower revenue estimates for Cologuard adoption. Price target lowered to $24 from $29.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use